Background
Methods
Results
Characteristics | RS < 25 | RS ≥ 25 | P |
---|---|---|---|
Total, n (%) | 1429 (81) | 329 (19) | – |
Age, median (interquartile range) | 53 (47–61) | 56 (48–64) | 0.002 |
Stage, n (%) | 0.61 | ||
I | 996 (70) | 234 (71) | |
II | 433 (30) | 95 (29) | |
Surgery type, n (%) | 0.46 | ||
Breast-conserving surgery | 1013 (71) | 240 (73) | |
Mastectomy | 416 (29) | 89 (27) | |
Adjuvant chemotherapy, n (%) | < 0.001 | ||
No | 1173 (82) | 81 (25) | |
Yes | 256 (18) | 248 (75) | |
Adjuvant hormonal therapy, n (%) | 0.009 | ||
No | 63 (4) | 26 (8) | |
Yes | 1366 (96) | 303 (92) | |
Adjuvant chemotherapy and hormonal therapy group, n (%) | < 0.001 | ||
Adjuvant hormonal therapy without chemotherapy | 1125 (79) | 74 (22) | |
Both adjuvant chemotherapy and hormonal therapy | 241 (17) | 229 (70) | |
Adjuvant chemotherapy without hormonal therapy | 15 (1) | 19 (6) | |
Neither adjuvant chemotherapy nor hormonal therapy | 48 (3) | 7 (2) | |
Postoperative radiation, n (%) | 0.77 | ||
No | 397 (28) | 94 (29) | |
Yes | 1032 (72) | 235 (71) | |
Number of events, n | – | ||
iLRR | 18 | 4 | |
DM without iLRR | 11 | 9 | |
Death without iLRR or DM | 7 | 6 |
Treatment subgroup | |||||||||
---|---|---|---|---|---|---|---|---|---|
Adjuvant hormonal therapy | Yes | Yes | No | ||||||
Adjuvant chemotherapy | No | Yes | Yes or No | ||||||
Characteristics | RS < 25 | RS ≥ 25 | P | RS < 25 | RS ≥ 25 | P | RS < 25 | RS ≥ 25 | P |
Total, n (%) | 1125 (94) | 74 (6) | – | 241 (51) | 229 (49) | – | 63 (71) | 26 (29) | – |
Age, median (interquartile range) | 54 (48–62) | 65 (54–70) | < 0.001 | 49 (44–56) | 54 (46–62) | < 0.001 | 52 (46–63) | 53 (45–63) | 0.96 |
Stage, n (%) | 0.18 | 0.09 | 0.15 | ||||||
I | 799 (71) | 58 (78) | 153 (63) | 162 (71) | 44 (70) | 14 (54) | |||
II | 326 (29) | 16 (22) | 88 (37) | 67 (29) | 19 (30) | 12 (46) | |||
Surgery type, n (%) | 0.03 | 0.37 | 0.81 | ||||||
Breast-conserving surgery | 812 (72) | 62 (84) | 159 (66) | 160 (70) | 42 (67) | 18 (69) | |||
Mastectomy | 313 (28) | 12 (16) | 82 (34) | 69 (30) | 21 (33) | 8 (31) | |||
Postoperative radiation, n (%) | 0.84 | 0.86 | 0.59 | ||||||
No | 301 (27) | 19 (26) | 66 (27) | 61 (27) | 30 (52) | 14 (46) | |||
Yes | 824 (73) | 55 (74) | 175 (73) | 168 (73) | 33 (48) | 12 (54) | |||
Number of events, n | – | – | – | ||||||
iLRR | 16 | 3 | 1 | 1 | 1 | 0 | |||
DM without iLRR | 9 | 2 | 2 | 6 | 0 | 1 | |||
Death without iLRR or DM | 7 | 3 | 0 | 2 | 0 | 1 |
Treatment group | Competing risk regression for iLRR | 60-month cumulative incidence of iLRR (95% CI) | |
---|---|---|---|
HR (95% CI) | P | ||
Entire cohort | |||
RS < 25 | 1.0 (reference) | 1.8% (1.0–3.0%) | |
RS ≥25 | 1.14 (0.39–3.36) | 0.81 | 3.2% (1.0–7.6%) |
Hormonal therapy without chemotherapy | |||
RS < 25 | 1.0 (reference) | 1.9% (1.0–3.3%) | |
RS ≥25 | 3.66 (1.07–12.5) | 0.04 | 10.3% (2.2–25.7%) |
Hormonal therapy without chemotherapy | Competing risk regression for iLRR | 60-month cumulative incidence of iLRR (95% CI) | |
---|---|---|---|
HR (95% CI) | Ptrend | ||
RS < 18 | 1.0 (reference) | 0.02 | 1.2% (0.5–2.8%) |
RS 18–24 | 1.66 (0.59–4.66) | 3.7% (1.5–7.7%) | |
RS 25–30 | 3.59 (0.78–16.6) | 7.3% (1.0–22.7%) | |
RS ≥31 | 7.05 (0.97–51.3) | 33.3% (0.9–77.4%) |